Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2014 September;39(3) > Minerva Endocrinologica 2014 September;39(3):175-87

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

  GYNECOLOGICAL ENDOCRINOLOGY


Minerva Endocrinologica 2014 September;39(3):175-87

language: English

Oral contraceptives in polycystic ovary syndrome

Helvaci N., Yildiz B. O.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Hacettepe University School of Medicine, Hacettepe, Ankara, Turkey


PDF  


Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of reproductive age and combined oral contraceptives (OCs) are often the first-line treatment of the syndrome by improving hyperandrogenism and regulating menstrual cycles. Oral contraceptives have some cardiovascular and metabolic effects that varies among different formulations depending upon the dose and type of the both estrogen and progestin components. These cardiometabolic effects of OCs raise some concerns about their long-term use in PCOS, but available data suggest that the benefits outweigh the risks. More studies are needed to clarify the safety of long-term use of OCs in PCOS.

top of page

Publication History

Cite this article as

Corresponding author e-mail

yildizbo@yahoo.com